ADMA Biologics (ADMA) Stock: Buy, Sell, or Hold?
ADMA - ADMA Biologics, Inc.
$11.01
-0.22 (-1.96%)
▼
5d:
+6.48%
30d:
+12.23%
90d:
+31.54%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 04, 2026
12d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Oct 20, 2026 at $11.17 · last confirmed Oct 21, 2026
Strength: 8.0/10
Get Alerted When ADMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ADMA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ADMA shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$18.51
Based on 11.2% avg growth
INTRINSIC VALUE TODAY
$11.49
4.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ADMA is currently trading at $11.01, which is considered extended relative to its 30-day fair value range of $9.31 to $10.62. The stock's valuation (Forward PE: 11.7) is in line with its historical norms (11.6). At these levels, the market is pricing in 0.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ADMA is in a strong uptrend. The price is approaching resistance at $11.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ADMA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.00 (+54.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ADMA is in a strong uptrend. The price is approaching resistance at $11.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ADMA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.00 (+54.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$9.31 -
$10.62
Company Quality Score
27/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
29.5%
Protect Your Profits
Holding ADMA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 54.4% below Wall St target ($17.00)
- NEUTRAL: Market pricing in 0.2% annual earnings growth - fairly valued
- WARNING: Composite score 27/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$9.31 -
$10.62
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$10.03
Resistance Level
$11.33
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.67
Wall Street Target
$17.00
(+54.4%)
Revenue Growth (YoY)
2.0%
Earnings Growth (YoY)
14.3%
Profit Margin
33.0%
Valuation Premium vs History
+0.2% premium
PE vs Historical
11.7 vs 11.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.2%
(market-implied from PE analysis)
1-Year Target
$11.03
(+0%)
2-Year Target
$11.05
(+0%)
3-Year Target
$11.08
(+1%)
3-Yr Target (if PE normalizes)
(PE: 12→12)
PE COMPRESSION
$11.01
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 18.4%)
$31.10
(+182%)
Base:
(SPY PE: 11.7, Growth: 18.4%)
$18.27
(+66%)
Bear:
(PE: 9.9, Growth: 18.4%)
$15.53
(+41%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 16.04 | Current EPS (TTM): $0.70
Bull Case
$16.65
(+51%)
Analyst growth 34.8%, PE expands to 17.7
Base Case
$15.13
(+38%)
Market implied 34.8%, PE stable at 16.0
Bear Case
$7.64
(-31%)
Severe decline -20.0%, PE contracts to 13.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 22, 2026 9:12 AM ET
Data refreshes hourly during market hours. Next update: 10:12 AM
Data refreshes hourly during market hours. Next update: 10:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 58 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 47 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 58 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 59 HOLD |
Advanced ADMA Option Strategies
Professional options setups generated by AI based on today's ADMA price and gamma walls.
